This site is intended for healthcare professionals
Medical search
insulin detemir
FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
- differs from human insulin in that it has the terminal amino acid (B30)
in the B-chain deleted, and a 14-carbon fatty acid attached at position B29
- has
a prolonged duration of action (up to 24 hours) mediated by two mechanisms:
- mainly via , albumin binding via the fatty acid side-chain, which retains insulin in the subcutaneous depot
- strong self-association of insulin detemir hexamers at the injection site
- licensed for the treatment of diabetes, to be administered subcutaneously once or twice daily depending on patients' needs, in combination with meal-related short- or rapid-acting insulin
- efficacy and safety of insulin detemir have not been studied in children and adolescents, nor is there any clinical trial experience in pregnancy
- a review concluded
that (1):
- both insulin detemir and insulin glargine seem to result in glycaemic control that is at least comparable to that with isophane insulin
- insulin detemir appears to reduce nocturnal hypoglycaemia and result in less weight gain than does isophane insulin in patients with type 1 diabetes
- has
a prolonged duration of action (up to 24 hours) mediated by two mechanisms:
Reference:
- Drug and Therapeutics Bulletin (2004); 42(10):77-80.
Last reviewed 01/2018
Links: